[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566975":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":35,"responsibleParty":250,"collaborators":252,"id":255,"slug":25,"hasResults":256,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":256,"sex":262,"minAge":263,"maxAge":25,"enrollmentInfo":264,"targetDuration":25,"studyType":267,"phases":268,"briefSummary":270,"conditions":271,"keywords":276,"overallStatus":107,"whyStopped":25,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},{"fullName":5,"class":6},"i-Lumen Scientific AUS PTY LTD","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active i-Lumen AMD therapy","EXPERIMENTAL","Active transpalpebral microcurrent therapy",[13],"Device: i-Lumen AMD",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham i-Lumen AMD therapy","SHAM_COMPARATOR","Sham transpalpebral microcurrent therapy",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","i-Lumen AMD","i-Lumen AMD transpalpebral microcurrent stimulation system",[9,15],null,[27],{"name":28,"affiliation":5,"role":29},"Meredith Mundy","STUDY_DIRECTOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},"CONTACT","408-440-7049","mmundy@i-lumen.com.au",[36,57,72,89,105,124,141,153,168,186,201,218,234],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Retina Consultants PC","NOT_YET_RECRUITING","Manchester","Connecticut","06042","United States",{"type":44,"coordinates":45},"Point",[46,47],-72.52148,41.77593,{"lat":47,"lon":46},[50,54],{"name":51,"role":32,"phone":52,"phoneExt":25,"email":53},"Chris Research Coordinator","860-646-7704 x113","cdwy@retinact.com",{"name":55,"role":56,"phone":25,"phoneExt":25,"email":25},"Noam Rudnick, MD","PRINCIPAL_INVESTIGATOR",{"facility":58,"status":38,"city":59,"state":60,"zip":61,"country":42,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"University Retina & Macula Associates","Lemont","Illinois","60439",{"type":44,"coordinates":63},[64,65],-88.00173,41.67364,{"lat":65,"lon":64},[68],{"name":69,"role":32,"phone":70,"phoneExt":25,"email":71},"Clinical Research Manager","708-765-4110","maggieb@uretina.com",{"facility":73,"status":38,"city":74,"state":75,"zip":76,"country":42,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Texas Retina Associates","Fort Worth","Texas","76104",{"type":44,"coordinates":78},[79,80],-97.32085,32.72541,{"lat":80,"lon":79},[83,87],{"name":84,"role":32,"phone":85,"phoneExt":25,"email":86},"Lori Research Coordinator","817-334-0882 x411","lmullen@texasretina.com",{"name":88,"role":56,"phone":25,"phoneExt":25,"email":25},"Patrick Williams, MD",{"facility":90,"status":38,"city":91,"state":75,"zip":92,"country":42,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Tyler Retina Research Insitute","Tyler","75703",{"type":44,"coordinates":94},[95,96],-95.30106,32.35126,{"lat":96,"lon":95},[99,103],{"name":100,"role":32,"phone":101,"phoneExt":25,"email":102},"Melissa Long Research Coordinator","903-597-4644","mlong@tylerretina.com",{"name":104,"role":56,"phone":25,"phoneExt":25,"email":25},"Samuel Minaker, MD",{"facility":106,"status":107,"city":108,"state":109,"zip":110,"country":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Sydney Eye Hospital","RECRUITING","Sydney","New South Wales","2000","Australia",{"type":44,"coordinates":113},[114,115],151.20732,-33.86785,{"lat":115,"lon":114},[118,122],{"name":119,"role":32,"phone":120,"phoneExt":25,"email":121},"i-SIGHT2 MRG Coordinator","+61 2 9382 7309","i-sight2.mrg.coordinator@groups.sydney.edu.au",{"name":123,"role":56,"phone":25,"phoneExt":25,"email":25},"Samantha Fraser-Bell, BSc, MBBS, MHA, MPH, PhD",{"facility":125,"status":107,"city":126,"state":127,"zip":128,"country":111,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Hobart Eye Surgeons","Hobart","Tasmania","7000",{"type":44,"coordinates":130},[131,132],147.32941,-42.87936,{"lat":132,"lon":131},[135,139],{"name":136,"role":32,"phone":137,"phoneExt":25,"email":138},"Jackie Research Coordinator","+61 (03) 6210 6000","Jacqueline.Townley@eyesurgeons.com.au",{"name":140,"role":56,"phone":25,"phoneExt":25,"email":25},"Nitin Verma, MD, MBBS",{"facility":142,"status":107,"city":143,"state":144,"zip":145,"country":111,"cosmosGeoPoint":25,"geoPoint":25,"contacts":146},"Adelaide Eye & Retina Centre","Adelaide","Victoria","5000",[147,151],{"name":148,"role":32,"phone":149,"phoneExt":25,"email":150},"Kerin Research Coordinator","+61 08 8212 3022","khaywood@adelaideeye.com.au",{"name":152,"role":56,"phone":25,"phoneExt":25,"email":25},"Jagjit Jolly Gilhotra",{"facility":154,"status":107,"city":155,"state":144,"zip":25,"country":111,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Cerulea","East Melbourne",{"type":44,"coordinates":157},[158,159],144.9879,-37.81667,{"lat":159,"lon":158},[162,166],{"name":163,"role":32,"phone":164,"phoneExt":25,"email":165},"Regina Research Coordinator","+61 3 9959 0050","RCallegher@ceruleaclinicaltrials.org.au",{"name":167,"role":56,"phone":25,"phoneExt":25,"email":25},"Robyn Guymer",{"facility":169,"status":107,"city":170,"state":171,"zip":172,"country":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Auckland Eye Limited","Remuera","Auckland","1050","New Zealand",{"type":44,"coordinates":175},[176,177],174.79819,-36.88041,{"lat":177,"lon":176},[180,184],{"name":181,"role":32,"phone":182,"phoneExt":25,"email":183},"Alice Research Coordinator","64 09 529 2480","Alice@aucklandeye.co.nz",{"name":185,"role":56,"phone":25,"phoneExt":25,"email":25},"Riyaz Bhikoo",{"facility":187,"status":107,"city":188,"state":25,"zip":25,"country":173,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Southern Eye Specialist","Christchurch",{"type":44,"coordinates":190},[191,192],172.63333,-43.53333,{"lat":192,"lon":191},[195,199],{"name":196,"role":32,"phone":197,"phoneExt":25,"email":198},"Marie Research Coordinator","64 03 355 6397","marie@southerneye.co.nz",{"name":200,"role":56,"phone":25,"phoneExt":25,"email":25},"James Borthwick",{"facility":202,"status":107,"city":203,"state":25,"zip":204,"country":205,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"King's College Hospital","London","SE5 9RS","United Kingdom",{"type":44,"coordinates":207},[208,209],-0.12574,51.50853,{"lat":209,"lon":208},[212,216],{"name":213,"role":32,"phone":214,"phoneExt":25,"email":215},"Nikki Research Coordinator","+44 203 299 7791","noimottimson@nhs.net",{"name":217,"role":56,"phone":25,"phoneExt":25,"email":25},"Timothy Jackson, PhD, FRCOphth",{"facility":219,"status":107,"city":220,"state":25,"zip":221,"country":205,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"London North West University Healthcare","Middlesex","HA1 3UJ",{"type":44,"coordinates":223},[224,225],-0.26856,51.53174,{"lat":225,"lon":224},[228,232],{"name":229,"role":32,"phone":230,"phoneExt":25,"email":231},"Sandali Research Coordinator","+44 (0) 208 453 2077","snammuniarachchge@nhs.net",{"name":233,"role":56,"phone":25,"phoneExt":25,"email":25},"Christiana Dinah, BSc, MB BS, MRes, FRCOphth",{"facility":235,"status":107,"city":236,"state":25,"zip":237,"country":205,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"Sunderland Eye Infirmary","Sunderland","SR2 9HP",{"type":44,"coordinates":239},[240,241],-1.38222,54.90465,{"lat":241,"lon":240},[244,248],{"name":245,"role":32,"phone":246,"phoneExt":25,"email":247},"SEI Research Nurses Research Coordinator","0191 5699074","stsft.seiresearchnurses@nhs.net",{"name":249,"role":56,"phone":25,"phoneExt":25,"email":25},"Ajay Kotagiri",{"type":251,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[253],{"name":254,"class":6},"i-Lumen Scientific, Inc.","100566975",false,"NCT06662162","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.","i-SIGHT2","Key Inclusion Criteria:\n\n* Presence of at least one large druse \\>125 microns in diameter due to AMD.\n* BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6\u002F12 to 6\u002F60 \\[20\u002F40 to 20\u002F200\\])\n\nKey Exclusion Criteria:\n\n* Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and\u002For cardiac defibrillator\u002Fpacemaker.\n* Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and\u002For the grounding electrode (base of the hairline on the back of the neck).\n* Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) \\>10% (13.3 mmol\u002FL).\n* Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).\n* Known severe allergy to fluorescein dye.\n* Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).\n* History of seizure disorders, chronic migraines and\u002For cluster headaches.\n* History and\u002For evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.\n* Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).\n* History and\u002For evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.\n* GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.\n* History of intravitreal injections for GA (e.g., Syfovre or Izervay).\n* Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.\n* Glaucoma requiring ≥3 medications and\u002For drops per day, or history of trabeculectomy.\n* History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.\n* History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \\\u003C1 month from Screening.\n* Visually significant cataracts and\u002For visually significant posterior capsular opacification.\n* History of amblyopia.","ALL","60 Years",{"count":265,"type":266},100,"ESTIMATED","INTERVENTIONAL",[269],"NA","The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.\n\nParticipants will:\n\n* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.\n* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.",[272,273,274,275],"Age-Related Macular Degeneration","Age-related Macular Degeneration (ARMD)","Intermediate AMD","Geographic Atrophy Secondary to Age-related Macular Degeneration",[277,274,278,279],"AMD","Dry AMD","Geographic Atrophy","2026-05-01",{"date":282,"type":283},"2026-05-04","ACTUAL",{"date":285,"type":283},"2025-05-07",{"date":287,"type":266},"2029-12-31",{"name":5,"class":6},13]